No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Activ Surgical New Appointments

Richard Stamm as Vice President, General Counsel and Mark Johnson as Vice President, Global Sales

Editor: What To Know

  • “Activ Surgical is growing rapidly after our Series B fundraise in September of this year, and Rich and Mark will both play critical roles in continuing this upward trajectory and ensuring success for the commercial launch of our first product–the ActivInsights software suite–in 2022,” said Todd, Usen, chief executive officer, Activ Surgical.
  • “With preventable surgical errors costing our global healthcare system approximately $36 billion dollars, Activ Surgical and its innovative technology platform have a massive opportunity to usher in a new era of patient care and safety in the operating room,” said Johnson.
  • Most recently, he maintained his own legal and consulting firm, leveraging his practical business law and corporate governance expertise to advise a variety of businesses and their leaders.

Richard Stamm has been appointed vice president, general counsel, and Mark Johnson as vice president, global sales. In his role as general counsel, Stamm will oversee all aspects of Activ Surgical’s legal and corporate governance matters, while Johnson will spearhead the company’s sales organization.

These key executive appointments are being made between two significant company milestones–a $45 million Series B fundraise, announced in September 2021, and commercialization of its ActivInsights™ software suite, which is targeted for early 2022.

Richard Stamm brings 30 years of corporate and securities law experience to Activ Surgical. He started his career with leading law firm Dechert, LLP., before moving in-house at Ocean Spray Cranberries, Inc. where, as general counsel, he provided strategic guidance on the full range of legal issues faced by a global branded company. Following Ocean Spray, Stamm joined Agrify Corporation as its general counsel, helping to navigate the company through the legal complexities in preparing for its initial public offering (IPO). Most recently, he maintained his own legal and consulting firm, leveraging his practical business law and corporate governance expertise to advise a variety of businesses and their leaders. Stamm has a degree in business economics from Brown University and received his law degree from the University of Connecticut School of Law.

“I am excited to join Activ Surgical at a critical inflection point in the company’s history,” said Stamm. “With the impending commercial launch of its ActivInsight software suite, there is an abundance of interrelated commercial, business and regulatory activities to manage. I look forward to working with the Activ Surgical leadership team and the entire organization to guide them through these complexities.”

Johnson is a proven sales leader and executive with 20+ years of experience, and comes to Activ Surgical from Hologic, Inc., where he led the U.S. Commercial Skeletal business, as well as Western U.S. Breast and Skeletal Health team with collective sales and service revenue responsibility of $400M+. Across his leadership roles, he has excelled in his responsibilities of driving sales transformation, increasing revenue and profitability growth, attracting and selecting top talent, employee development, sales targeting and optimization, cross-functional leadership, culture development, and key account management. Previous to his time at Hologic, Johnson held leadership positions at Stryker, Smith & Nephew, and Elekta. He has a degree in biology from The University of Georgia.

“With preventable surgical errors costing our global healthcare system approximately $36 billion dollars, Activ Surgical and its innovative technology platform have a massive opportunity to usher in a new era of patient care and safety in the operating room,” said Johnson. “I plan to embrace the growth opportunities ahead as the company moves toward commercialization and am confident we will fulfill our mission to democratize surgical care around the globe.”

“Activ Surgical is growing rapidly after our Series B fundraise in September of this year, and Rich and Mark will both play critical roles in continuing this upward trajectory and ensuring success for the commercial launch of our first product–the ActivInsights software suite–in 2022,” said Todd, Usen, chief executive officer, Activ Surgical. “Both executives bring an outstanding track record in their respective fields, and I am thrilled to have them join our leadership team.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy